en · de · es · fr · pt
sr9009-notes.peptides6608.com › Guide › Background And Research Status — Complete Guide

Background And Research Status — Complete Guide

By Editorial Desk · published 2026-05-14 · last reviewed 2026-06-23 · Guide

mitochondrial biogenesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-06-23. Anything still debated is marked as such rather than presented as settled.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Related pages on this site

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Further detail

The increase in dopamine release is prominent in drug use, specifically in the ventral striatum and the nucleus accumbens. Dopamine release in this pathway is more closely tied to motivation — the "wanting" of a reward — than to the pleasure, or "liking", that the reward itself produces, which depends on separate brain systems. Addictive drugs cause a significant increase in this reward system, causing a large increase in dopamine signaling as well as increase in reward-seeking behavior, in turn motivating drug use. This promotes the development of a maladaptive drug to stimulus relationship. Early drug use leads to these maladaptive associations, later affecting cognitive processes used for coping, which are needed to abstain from them successfully.

=== Histidine === Histidine complexes comprise an important subset of transition metal amino acid complexes. In common with other 4/5-substituted imidazoles, histidine can coordinate to metals via either of two nonequivalent tautomers. The free amino acid can coordinate through the imidazole and either or both of the carboxylate and amine. The imidazole side chain of histidine residues in proteins are common binding sites for metal ions. Unlike the free amino acid, the histidine residue (i.e., as a component of a peptide or protein), coordinates solely via the imidazole substituent. Examples include myoglobin (Fe), carbonic anhydrase (Zn), azurin (Cu), and alpha-ketoglutarate-dependent hydroxylases (Fe). Polyhistidine-tag ("his tag") is an amino acid motif in proteins consisting of several histidine (His) residues that is attached to proteins to facilitate purification. The concept relies on the affinity of the imidazole side chain for metal cations.

==== Skinless ==== "Skinless" hot dogs use a casing for cooking, but the casing may be a long tube of thin cellulose that is removed between cooking and packaging, a process invented in Chicago in 1925 by Erwin O. Freund, founder of Visking. The first skinless hot dog casings were produced by Freund's new company under the name "Nojax", short for "no jackets" and sold to local Chicago sausage makers. Skinless hot dogs vary in surface texture, but have a softer "bite" than with natural casing. Skinless hot dogs are more uniform in shape and size and cheaper to make than natural casing hot dogs.

== Compounds == The alkali metals form complete series of compounds with all usually encountered anions, which well illustrate group trends. These compounds can be described as involving the alkali metals losing electrons to acceptor species and forming monopositive ions. This description is most accurate for alkali halides and becomes less and less accurate as cationic and anionic charge increase, and as the anion becomes larger and more polarisable. For instance, ionic bonding gives way to metallic bonding along the series NaCl, Na2O, Na2S, Na3P, Na3As, Na3Sb, Na3Bi, Na.

== Alternative pathway == Plants, most bacteria, and some protozoa such as malaria parasites have the ability to produce isoprenoids using an alternative pathway called the methylerythritol phosphate (MEP) or non-mevalonate pathway. The output of both the mevalonate pathway and the MEP pathway are the same, IPP and DMAPP; however, the enzymatic reactions to convert acetyl-CoA into IPP are entirely different. Interaction between the two metabolic pathways can be studied by using 13C-glucose isotopomers. In higher plants, the MEP pathway operates in plastids while the mevalonate pathway operates in the cytosol. Examples of bacteria that contain the MEP pathway include Escherichia coli and pathogens such as Mycobacterium tuberculosis.

Sources: en.wikipedia.org

Supporting material

=== Remaining undifferentiated === Most UCTD cases will remain undifferentiated. UCTD itself usually has a mild clinical course, particularly if there is low organ involvement. Most patients who remain undifferentiated tend not to experience major organ involvement. Up to 10–20% of patients diagnosed with UCTD will never progress to a defined disease, and their symptoms will decrease or disappear. About 12% of patients will go into remission.

== Measurement == The glycemic index of a food is defined as the incremental area under the two-hour blood glucose response curve (AUC) following a 12-hour fast and ingestion of a food with a certain quantity of available carbohydrate (usually 50 g). The AUC of the test food is divided by the AUC of the standard (either glucose or white bread, giving two different definitions) and multiplied by 100. The average GI value is calculated from data collected in 10 human subjects. Both the standard and test food must contain an equal amount of available carbohydrate. The result gives a relative ranking for each tested food. Foods with carbohydrates that break down quickly during digestion and release glucose rapidly into the bloodstream tend to have a high GI; foods with carbohydrates that break down more slowly, releasing glucose more gradually into the bloodstream, tend to have a low GI. A lower glycemic index suggests slower rates of digestion and absorption of the foods' carbohydrates and can also indicate greater extraction from the liver and periphery of the products of carbohydrate digestion. The current validated methods use glucose as the reference food, giving it a glycemic index value of 100 by definition. This has the advantages of being universal and producing maximum GI values of approximately 100. White bread can also be used as a reference food, giving a different set of GI values (if white bread = 100, then glucose ≈ 140).

=== Others === Radiation therapy and tamoxifen have been shown to help prevent gynecomastia and breast pain from developing in prostate cancer patients who will be receiving androgen deprivation therapy. The efficacy of these treatments is limited once gynecomastia has occurred and is therefore most effective when used prophylactically. In the United States, many insurance companies deny coverage for surgery for gynecomastia treatment or male breast reduction on the basis that it is a cosmetic procedure.

Males expel urine from the bladder through the urethra, which passes through the prostate where it is joined by the ejaculatory ducts, and then onward through the penis. At the root of the penis (the proximal end of the corpus spongiosum) lies the external sphincter muscle, which relaxes during urination. This is a small sphincter of striated muscle tissue and is in healthy males, under voluntary control. Physiologically, urination involves coordination between the central, autonomic, and somatic nervous systems. In infants, some elderly individuals, and those with neurological injury, urination may occur as an involuntary reflex. Brain centers that regulate urination include the pontine micturition center, periaqueductal gray, and the cerebral cortex. During erection, these centers block the relaxation of the sphincter muscles, so as to act as a physiological separation of the excretory and reproductive function of the penis, and preventing urine from entering the upper portion of the urethra during ejaculation.

In particular, mimic miRNAs are used to introduce miRNAs that act as tumor suppressors into cancerous tissues, while miRNA antagonists are used to target oncogenic miRNAs to prevent their cancer-promoting activity. Therapeutic miRNA is also used in addition to common therapies (such as cancer therapies) that are known to overexpress or destabilize the patient miRNA levels. An example of one mimic miRNA therapy that demonstrated efficacy in impeding lung cancer tumor growth in mouse studies is miR-34a. One concerning aspect of miRNA-based therapies is the potential for the exogeneous miRNA to affect miRNA silencing mechanisms within normal body cells, thereby affecting normal cellular biochemical pathways. However, in vivo studies have indicated that miRNAs display little to no effect in non-target tissues/organs.

Sources: en.wikipedia.org

Supporting material

In the Middle Ages the regions situated on the mountainous border of the Duchy and the Kingdom of Bohemia (Crown of Saint Václav) had since the Migration Period been settled mainly by western Slavic Czechs. Along the Bohemian Forest in the west, the Czech lands bordered on the German Slavic tribes (German Sorbs) stem duchies of Bavaria and Franconia; marches of the medieval German kingdom had also been established in the adjacent Austrian lands south of the Bohemian-Moravian Highlands and the northern Meissen region beyond the Ore Mountains. In the course of the Ostsiedlung (settlement of the east), German settlement from the 13th century onwards continued to move into the Upper Lusatia region and the duchies of Silesia north of the Sudetes mountain range. From as early as the second half of the 13th century onwards these Bohemian border regions were settled by ethnic Germans, who were invited by the Přemyslid Bohemian kings—especially by Ottokar II (1253–1278) and Wenceslaus II (1278–1305). After the extinction of the Přemyslid dynasty in 1306, the Bohemian nobility backed John of Luxembourg as king against his rival Duke Henry of Carinthia. In 1322, King John of Bohemia acquired (for the third time) the formerly Imperial Egerland region in the west and vassalized most of the Piast Silesian duchies, as acknowledged by King Casimir III of Poland by the 1335 Treaty of Trentschin. His son, Bohemian King Charles IV, was elected King of the Romans in 1346 and crowned Holy Roman Emperor in 1355.

=== Constituent and neighbouring settlements === The Billericay built up area includes the Queen's Park, Sunnymede, Great Burstead, South Green and Noak Hill localities. Neighbouring settlements include Stock to the north, Ramsden Heath and Ramsden Bellhouse to the east, Basildon to the south, Little Burstead to the south-west, and Havering's Grove to the west. Billericay is within the London Basin and lies on a mixture of London clay, Claygate Beds and Bagshot Beds on the higher ground. The point where the soils change from sandy to impermeable clay creates springs.

The strain lacked the outer membrane proteins OmpF and OmpC, and showed increased expression of a multidrug efflux pump, but did not produce carbapenemase. CR Pseudomonas aeruginosa is commonly present in intensive-care units, and can lead to dangerous infections. In Thai hospitals, of 261 multidrug-resistant samples collected of P. aeruginosa (not part of the Enterobacteriaceae), 71.65% were carbapenem-resistant.

Bonaparte returned to France from Egypt on 23 August 1799, his campaign there having failed. He seized control of the French government on 9 November, in a bloodless coup d'état, replacing the Directory with the Consulate and transforming the republic into a de facto dictatorship. He further reorganised the French military forces, establishing a large reserve army positioned to support campaigns on the Rhine or in Italy. Russia had already been knocked out of the war, and, under Napoleon's leadership, the French decisively defeated the Austrians in June 1800, crippling Austrian capabilities in Italy. Austria was definitively defeated that December, by Moreau's forces in Bavaria. The Austrian defeat was sealed by the Treaty of Lunéville early the following year, further compelling the British to sign the Treaty of Amiens with France, establishing a tenuous peace.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

Network